Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) is a publicly traded Healthcare sector company. As of November 6, 2026, QNTM trades at $2.12 with a market cap of $17.87M and a P/E ratio of 0.00. QNTM moved -3.62% today. Year to date, QNTM is -70.82%; over the trailing twelve months it is -76.56%. Its 52-week range spans $2.05 to $38.25. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces QNTM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
US judge consolidates Quantum BioPharma stock-manipulation suits against CIBC, RBC: A Manhattan federal judge consolidated Quantum BioPharma’s lawsuit with a shareholder class action alleging stock manipulation from Jan. 1, 2020, to Aug. 15, 2024, and appointed Grant & Eisenhofer as lead counsel.
| Metric | Value |
|---|---|
| Price | $2.12 |
| Market Cap | $17.87M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $38.25 |
| 52-Week Low | $2.05 |
| Volume | 77.16K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover QNTM: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.